Prognosis

Johnson & Johnson Begins Giant Study of One-Dose Covid Shot

Company to join other vaccine makers releasing study details
Late-stage trial begins nearly two months after frontrunners

J&J Chief Scientific Officer Paul Stoffels says the single-dose vaccine could be a very effective tool.Source: Bloomberg)

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Robert Langreth and Riley Griffin

September 23, 2020 at 10:45 AM UTC

Updated on

September 23, 2020 at 2:35 PM UTC

This article is for subscribers only.

Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.

Johnson & Johnson has begun dosing up to 60,000 volunteers in a study of its Covid-19 vaccine, marking the first big U.S. trial of an inoculation that may work after just one shot.